Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Back to Agenda

Session 1: The Basics: Why We Do What We Do

Session Chair(s)

JP Clement, MD

Founder and Principal

JPCC Associates, United States

This session provides longitudinal context for the evolving safety profile of a medicinal product and why continuous safety monitoring and evaluation are important. Three case studies underscore the importance of impeccable attention to drug safety during all phases of clinical development.

Have an account?

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Session 1: The Basics: Why We Do What We Do

Session Chair(s)

JP Clement, MD

Be informed and stay engaged.